Baidu
map

Eur Rev Med Pharmacol Sci:长链非编码RNA H19通过Wnt /β-catenin信号通路促进大鼠外胚间充质干细胞的成骨分化

2018-12-29 MedSci MedSci原创

本研究旨在探究长非编码RNA(lncRNA)H19促进大鼠外胚间充质干细胞(EMSCs)的成骨分化的分子机制。通过流式细胞术从大鼠胎儿面部过程中分离EMSC。通过荧光免疫测定检测成骨标志物CD29,CD90,CD44,CD57,巢蛋白和sox10。瞬时干扰H19构建后,即稳定表达H19 的EMSCs细胞系,使用实时聚合酶链反应(RT-PCR)和Western blot检测β-catenin和Wnt

本研究旨在探究长非编码RNA(lncRNA)H19促进大鼠外胚间充质干细胞(EMSCs)的成骨分化的分子机制。

通过流式细胞术从大鼠胎儿面部过程中分离EMSC。通过荧光免疫测定检测成骨标志物CD29,CD90,CD44,CD57,巢蛋白和sox10。瞬时干扰H19构建后,即稳定表达H19 的EMSCs细胞系,使用实时聚合酶链反应(RT-PCR)和Western blot检测β-catenin和Wnt通路靶基因,并诱导EMSCs细胞成骨分化。使用Wnt /β-catenin信号通路抑制剂Wnt-C59处理过表达H19的EMSCs,通过RT-PCR和Western blot检测β-catenin和成骨标志物的表达。此外,通过转染miR-22和miR-141模拟物和荧光素酶报告基因测定来探索H19调节Wnt /β-连环蛋白信号传导途径的机制。

结果显示,研究成功分离并鉴定了EMSCs,成骨标志物CD29,CD90,CD44,CD57,巢蛋白和sox10明显过表达。成骨诱导的溶液明显增加EMS19中H19和成骨标志物ALP,Runx2,BMP和OCN的表达(p <0.05)。干扰H19明显抑制Wnt /β-catenin信号通路的成骨标志物,β-连环蛋白和靶基因的表达(p <0.05),而H19的上调则显著促进EMSCs中这些标志物和基因的表达(p <0.05)。Wnt-C59抑制剂治疗在具有H19过表达的EMSC中抑制Wnt /β-连环蛋白信号传导通路和成骨分化(p <0.05)。此外,H19可以阻断miR-22和miR-141对β-catenin的抑制作用,并在转染EMSC中的miR-22模拟物和miR-141模拟物后激活Wnt /β-catenin信号通路(p <0.05)。

综上所述,该研究结果表明,LncRNA H19通过激活Wnt /β-catenin信号促进大鼠EMSCs的成骨分化,为EMSCs在牙体组织工程再生修复中的应用提供理论依据。

原始出处:

Gong YY, Peng MY, et al., Long non-coding RNA H19 promotes the osteogenic differentiation of rat ectomesenchymal stem cells via Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8805-8813. doi: 10.26355/eurrev_201812_16648.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-11-02 HinsMax
  2. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-01-02 tidiq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-10-20 d830384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-03-02 yb6560
  8. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-01-12 jj000001
  9. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1821375, encodeId=ad5918213e5e7, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 02 23:28:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649712, encodeId=da691649e1264, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 02 05:28:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815422, encodeId=acd2181542201, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Thu Apr 18 02:28:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743486, encodeId=f6701e434860a, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Oct 20 07:28:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788347, encodeId=06341e88347b9, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 23 04:28:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908503, encodeId=2b3219085031c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 27 22:28:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996255, encodeId=c0781996255a9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Mar 02 17:28:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787568, encodeId=59221e87568cb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 12 05:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337519, encodeId=6233133e51956, content=<a href='/topic/show?id=863f5409610' target=_blank style='color:#2F92EE;'>#成骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54096, encryptionId=863f5409610, topicName=成骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351938, encodeId=8a5f1351938db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 31 12:28:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2018-12-31 zhaojie88
Baidu
map
Baidu
map
Baidu
map